Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-08-14 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
九届十四次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the company's 14th board meeting of the 9th session, including approval of the 2019 semi-annual report, a special report on the use of raised funds, acquisition of a 30% stake in another company, addition of fixed assets, and change in accounting policies. The document is not the report itself but an announcement of board decisions. It is not a full financial report, earnings release, or management discussion. It fits best under Board/Management Information (MANG) as it announces board resolutions and decisions.
2019-08-14 Chinese
关于回购注销部分限制性股票通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the repurchase and cancellation of a portion of restricted shares under the 2017 restricted stock incentive plan. It details the reasons for the repurchase, the number of shares involved, the impact on registered capital, and provides information for creditors to make claims within a specified period. The document is a formal notification to creditors about the company's share repurchase and capital reduction, including legal rights and procedures for creditors. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a report or presentation but an official announcement related to the company's transaction in its own shares (share repurchase and cancellation). Therefore, the appropriate classification is Transaction in Own Shares (POS). The document length is short (1451 characters), and it is not merely announcing a report but providing substantive information about the share cancellation and creditor notification, fitting the POS category.
2019-08-09 Chinese
2019年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement from a shareholders' meeting (临时股东大会决议公告) held on August 9, 2019. It details the meeting attendance, voting results on specific proposals, and legal witness statements confirming the validity of the meeting and resolutions. The content focuses on the official announcement of voting results from the shareholders' meeting rather than the meeting materials or the full report. The document length is short (2305 characters), and it is clearly an announcement of voting results rather than a full report or presentation. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-08-09 Chinese
2019年第二次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion from a law firm regarding the procedures, attendance, and voting results of Kunming Pharmaceutical Group Co., Ltd.'s 2019 second extraordinary general meeting (临时股东大会). It details the legality and validity of the meeting's convening, attendance, and resolutions passed. The document does not contain financial statements or detailed financial data, nor is it a report of the meeting itself or a presentation. It is a legal opinion related to a shareholders' meeting, specifically focusing on the voting results and legality of the meeting's resolutions. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting results and legal opinion, not a full report or announcement of a report publication.
2019-08-09 Chinese
2019年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2019 Second Extraordinary General Meeting" of KPC Pharmaceuticals, Inc. It contains detailed meeting agenda, voting procedures, and explanations of specific proposals related to the repurchase and cancellation of restricted stock incentive plans. The content is focused on the meeting itself, including the organization, voting rights, and detailed descriptions of the proposals to be voted on. There are no financial statements or comprehensive financial data presented, nor is this a transcript of a call or a report publication announcement. The document is clearly the presentation and materials shared during a shareholders' meeting, specifically an extraordinary general meeting. Therefore, it fits the category of AGM Information (AGM-R).
2019-08-02 Chinese
关于回购并注销2017年限制性股票激励计划已离职激励对象已获授但尚未解除限售部分限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the repurchase and cancellation of restricted shares granted under the 2017 restricted stock incentive plan to former employees who have left the company. It details the number of shares repurchased, the price, the approval process, the impact on share capital structure, and includes opinions from independent directors, the supervisory board, legal counsel, and financial advisors. The document is focused on a specific corporate action related to share repurchase and cancellation of restricted stock, not a financial report or earnings release. It is not a full annual or interim report, nor a regulatory filing about a report publication. The content fits the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares.
2019-07-19 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.